Ibrutinib monotherapy in relapsed or refractory, transformed diffuse large B-cell lymphoma

BACKGROUND: Histological transformation to diffuse large B-cell lymphoma (tDLBCL) occurs in a significant proportion of indolent lymphomas. However, few studies of novel agents inform its management, particularly when relapsed after or refractory (R/R) to prior treatment. PATIENTS AND METHODS: We pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Lymphoma Myeloma Leuk
Main Authors: Graf, Solomon A., Cassaday, Ryan D., Morris, Karolyn, Voutsinas, Jenna M., Wu, Qian Vicky, Behnia, Sanaz, Lynch, Ryan C., Krakow, Elizabeth, Rasmussen, Heather, Chauncey, Thomas R., Kanan, Sandra, Soma, Lorinda, Smith, Stephen D., Gopal, Ajay K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7904587/
https://ncbi.nlm.nih.gov/pubmed/33358575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2020.11.023
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados